Navigation Links
RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer
Date:12/14/2011

Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures. In the past 20 years, numerous treatment regimens have been evaluated for locally-advanced pancreatic cancer with high-dose chemotherapy followed by chemoradiation being the current standard approach. However, the median survival time of these patients remains generally less than 12 months.

Ganitumab is a fully-human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor, (IGF-1R). From preclinical studies, IGF-1R has been shown to play a significant role in tumor cell growth and in tumor cell's resistance to both chemotherapy and radiation treatment. The investigational drug ganitumab is thought to interrupt the process that changes normal cells into cancer, thereby stopping the abnormal growth behavior of a tumor and making it more amenable to chemoradiation treatment.

"Ganitumab is a therapy under investigation that has shown promising results in early-phase trials for patients with metastatic pancreatic cancer," says Christopher Crane, MD, Professor of Radiation Oncology at MD Anderson Cancer Center and principal investigator for the RTOG 1102 trial, Houston, "Collecting information about the best drug dose and safety of administering ganitumab with chemoradiation is critical to further evaluating the efficacy of this treatment regimen for patients with locally-advanced disease," explains Crane.

Up to 42 study participants at institutions across the United States will be enrolled in the trial and will receive 2 months of induction (high-dose) chemotherapy with gemcitabine and ganitumab to provide early systemic treatment and also to select the study participants most likely to benefit from chemoradiation. Previous RTOG studies, such as RTOG 0411, have shown no increase in toxicity during chemoradiation when induction chemotherapy is first administered.

Following induction chemotherapy, study participants will receive ganitumabfirst investigating doses of 12mg/kg and, if tolerated, subsequently 20 mg/kgalong with standard chemoradiation treatment. Upon treatment completion, participants will continue to receive maintenance doses of gemcitabine and ganitumab until tumor progression.

According to Walter Curran, MD, RTOG Group Chair and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "Amgen is conducting a phase III trial of ganitumab in metastatic pancreatic cancer. If trial results for treatment of metastatic disease are positive, moving forward with a randomized phase II trial for patients with locally advanced disease would be indicated. In this scenario, the RTOG 1102 trial results will expedite further evaluation of this targeted therapy."


'/>"/>
Contact: Nancy Fredericks
nfredericks@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
2. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
3. Consortium gets $7.2 million contract renewal to promote phase II clinical trials
4. ASU embarks on next phase of an effort to rapidly assess radiation dose
5. Phase II study shows new cancer drug combination significantly delays breast cancer progression
6. First Phase III trial of an alpha-pharmaceutical
7. Osteoporosis Phase III data at 2011 ASBMR Show oral calcitonin tablet is safe and effective
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
11. Neurologix presents 1-year data from phase 2 study of NLX-P101 in Parksinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, ... the 7th Edition of International Social Design Awards. , The 7th A' ... System Designers, Governments and Institutions worldwide with realized projects and conceptual works. , ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the ... in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on ... health management. , ODH will also have an exhibit booth where attendees may speak ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced ... Raymond James and Associates, 38 th ... in Orlando, FL. Cowen and ... on March 7, 2017 in Boston, MA. ... 2017 in Miami, FL. ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The ... a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from ... 9.1% from 2016 to 2027. The market is estimated at $816m ... ... on to discover how you can exploit the future business opportunities ...
(Date:2/27/2017)... October – December 2016 Revenues amounted to SEK 0.3 ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... amounted to SEK -39.5 (-29.5) million Result after tax amounted ...
Breaking Medicine Technology: